Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability

Nature Communications

Volumn 7, Issue , 2016, Pages

  Kong, Leopold ^a   He, Linling ^a   De Val, Natalia ^a   Vora, Nemil ^a   Morris, Charles D ^a   Azadnia, Parisa ^a   Sok, Devin ^a   Zhou, Bin ^a   Burton, Dennis R ^a,b   Ward, Andrew B ^a   Wilson, Ian A ^a   Zhu, Jiang ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 140; PEPTIDE; FURIN; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS ENVELOPE PROTEIN;

ANTIGEN; DESIGN; ELECTRON MICROSCOPY; HOST; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; MOLECULAR ANALYSIS; OPTIMIZATION; PEPTIDE; PROTEIN; STABILIZATION;

ANTIGENICITY; ARTICLE; ELECTRON MICROSCOPY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN STRUCTURE; VIRUS ENVELOPE; VIRUS STRAIN; METABOLISM; POLYMERIZATION; PROTEIN STABILITY; ULTRASTRUCTURE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FURIN; POLYMERIZATION; PROTEIN STABILITY;

EID: 84976633087     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12040     Document Type: Article

References (67)

1. Burton, D. R. et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396-407 (2012).
2. Burton, D. R., Mascola, J. R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571-576 (2015).
3. Checkley, M. A., Luttge, B. G., Freed, E. O. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J. Mol. Biol. 410, 582-608 (2011).
4. Wyatt, R., Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884-1888 (1998).
5. McKeating, J. A., McKnight, A., Moore, J. P. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J. Virol. 65, 852-860 (1991).
6. Harris, A. et al. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc. Natl Acad. Sci. USA 108, 11440-11445 (2011).
7. Yang, X. Z., Farzan, M., Wyatt, R., Sodroski, J. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 74, 5716-5725 (2000).
8. Yang, X. Z. et al. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J. Virol. 74, 4746-4754 (2000).
9. Yang, X. Z. et al. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76, 4634-4642 (2002).
10. Sanders, R. W. et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76, 8875-8889 (2002).
11. Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).
12. Yasmeen, A. et al. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology 11, 41 (2014).
13. Derking, R. et al. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog. 11, e1004767 (2015).
14. Julien, J.-P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477-1483 (2013).
15. Lyumkis, D. et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484-1490 (2013).
16. Pancera, M. et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514, 455-461 (2014).
17. Julien, J.-P. et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl Acad. Sci. USA 110, 4351-4356 (2013).
18. Blattner, C. et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40, 669-680 (2014).
19. Falkowska, E. et al. Broadly neutralizing HIV antibodies define a glycandependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40, 657-668 (2014).
20. Scharf, L. et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 7, 785-795 (2014).
21. Huang, J. et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515, 138-142 (2014).
22. Sok, D. et al. Recombinant HIV envelope trimer selects for quaternarydependent antibodies targeting the trimer apex. Proc. Natl Acad. Sci. USA 111, 17624-17629 (2014).
23. Pugach, P. et al. A native-like SOSIP.664 trimer based on an HIV-1 subtype B Env gene. J. Virol. 89, 3380-3395 (2015).
24. Julien, J.-P. et al. Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proc. Natl Acad. Sci. USA 112, 11947-11952 (2015).
25. de Taeye, S. W., Moore, J. P., Sanders, R. W. HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies. Trends Immunol. 37, 221-232 (2016).
26. Do Kwon, Y. et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat. Struct. Mol. Biol. 22, 522-531 (2015).
27. de Taeye, S. W. et al. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 163, 1702-1715 (2015).
28. Sanders, R. W. et al. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349, aac4223 (2015).
29. Georgiev, I. S. et al. Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 Env. J. Virol. 89, 5318-5329 (2015).
30. Sharma, S. K. et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep. 11, 539-550 (2015).
31. Guenaga, J. et al. Structure-guided redesign increases the propensity of HIV Env to generate highly stable soluble trimers. J. Virol. 90, 2806-2817 (2015).
32. Ulmer, J. B., Mason, P. W., Geall, A., Mandl, C. W. RNA-based vaccines. Vaccine 30, 4414-4418 (2012).
33. Robert-Guroff, M. Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol. 18, 546-556 (2007).
34. Liu, M. A. DNA vaccines: an historical perspective and view to the future. Immunol. Rev. 239, 62-84 (2011).
35. Garces, F. et al. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity 43, 1053-1063 (2015).
36. Lee, J. H., Ozorowski, G., Ward, A. B. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351, 1043-1048 (2016).
37. Wilson, I. A., Skehel, J. J., Wiley, D. C. Structure of the hemagglutinin membrane glycoprotein of influenza virus at 3Å resolution. Nature 289, 366-373 (1981).
38. Kong, L. et al. Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. Acta. Crystallogr. D Biol. Crystallogr. 71, 2099-2108 (2015).
39. Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
40. Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
41. Zhou, T. et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39, 245-258 (2013).
42. Wu, X. et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602 (2011).
43. Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
44. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
45. Burton, D. R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027 (1994).
46. Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100-1108 (1996).
47. Mascola, J. R. The modern era of HIV-1 vaccine development. Science 349, 139-140 (2015).
48. McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013).
49. Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177-U127 (2008).
50. Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).
51. Xiang, Z. X., Soto, C. S., Honig, B. Evaluating conformational free energies: the colony energy and its application to the problem of loop prediction. Proc. Natl Acad. Sci. USA 99, 7432-7437 (2002).
52. Zhu, J., Fan, H., Periole, X., Honig, B., Mark, A. E. Refining homology models by combining replica-exchange molecular dynamics and statistical potentials. Proteins 72, 1171-1188 (2008).
53. Elsliger, M.-A. et al. The JCSG high-throughput structural biology pipeline. Acta Crystallogr. F Struct. Biol. Cryst. Commun. 66, 1137-1142 (2010).
54. Otwinowski, Z., Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
55. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
56. Emsley, P., Lohkamp, B., Scott, W. G., Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
57. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
58. Lunin, V. Y., Afonine, P. V., Urzhumtsev, A. G. Likelihood-based refinement. I. Irremovable model errors. Acta Crystallogr. A 58, 270-282 (2002).
59. Martin, A. C. R. Accessing the Kabat antibody sequence database by computer. Proteins 25, 130-133 (1996).
60. Suloway, C. et al. Automated molecular microscopy: the new Leginon system. J. Struct. Biol. 151, 41-60 (2005).
61. Lander, G. C. et al. Appion: an integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. 166, 95-102 (2009).
62. Ogura, T., Iwasaki, K., Sato, C. Topology representing network enables highly accurate classification of protein images taken by cryo electron-microscope without masking. J. Struct. Biol. 143, 185-200 (2003).
63. Sorzano, C. O. S. et al. A clustering approach to multireference alignment of single-particle projections in electron microscopy. J. Struct. Biol. 171, 197-206 (2010).
64. Tang, G. et al. EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38-46 (2007).
65. Ludtke, S. J., Baldwin, P. R., Chiu, W. EMAN: Semiautomated software for high-resolution single-particle reconstructions. J. Struct. Biol. 128, 82-97 (1999).
66. Scheres, S. H. W. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519-530 (2012).
67. Scheres, S. H. W., Chen, S. Prevention of overfitting in cryo-EM structure determination. Nat. Methods 9, 853-854 (2012).